Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026
Globe Newswire•11/11/2026•16:05 ET
0
Key Highlights
- ➤Quarterly revenue $2.3 million, up approximately 28% year-over-year
- ➤Net loss $7.8 million, or $3.76 per share
- ➤2026 revenue guidance reaffirmed at $8 million, excluding second-generation LungFit PH
- ➤2027 revenue guidance reaffirmed at $16–$18 million, including second-generation LungFit PH
- ➤Second-generation LungFit PH PMA supplement remains under FDA review; audit-readiness expected mid-December
Expert Statements
Robert Goodman, Chief Executive Officer of Beyond Air
“Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval”
Robert Goodman, Chief Executive Officer of Beyond Air
“Our US pipeline is now experiencing unprecedented expansion with an acceleration in demand for our first-generation system and high receptivity to our technology and its operational efficiencies, creating a natural demand for our next generation product.”
Robert Goodman, Chief Executive Officer of Beyond Air
“We are especially pleased with the pace of new account wins and rate of renewals, which speak to the high level of customer satisfaction with our unique technology – all of which we believe we can leverage into the potential future launch of our second-generation LungFit PH system.”
Robert Goodman, Chief Executive Officer of Beyond Air
“Subject to FDA approval, the system is designed to provide a smaller footprint, reduced weight, simplified operation, longer service intervals and expanded operational flexibility.”
Robert Goodman, Chief Executive Officer of Beyond Air
“The PMA supplement seeks expanded FDA labeling that would permit use during patient transport by air and ground.”
Robert Goodman, Chief Executive Officer of Beyond Air
“We remain encouraged by our active and productive discussions with the FDA and the progress we are making toward completing the remaining steps in the review process for the second-generation LungFit PH system.”
Robert Goodman, Chief Executive Officer of Beyond Air
“We expect to complete our audit-readiness process in mid-December, and subject to FDA inspections and final approval thereafter.”
Record quarterly revenue of $2.3 million, representing approximately 28% year-over-year growth, reflecting continued adoption of first-generation LungFit PH
PMA supplement for second-generation LungFit PH system remains under FDA review; transport capability expected to drive greater market penetration, pending approval
Get started
Create a free account to read the full story.